Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosuvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosuvastatin SCHEMBL28393539 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240432 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL32686257 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL41433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL2520 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL3938301 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL154400 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL16995485 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL8268193 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL29722976 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185528-A1 | PROCESS FOR THE PREPARATION OF METHYL ESTER OF ROSUVASTATIN | Lek Pharmaceuticals D.D. (SI) | 2010-05-19 | — | — | EP | claimed |
| WO-2009019211-A1 | PROCESS FOR THE PREPARATION OF METHYL ESTER OF ROSUVASTATIN | LEK PHARMACEUTICALS D.D. (SI) | 2009-02-12 | — | — | WO | claimed |
| EP-2022784-A1 | Process for the preparation of methyl ester of rosuvastatin | LEK Pharmaceuticals D.D. (SI) | 2009-02-11 | — | — | EP | claimed |
| US-20240360086-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | API CORPORATION (JP) | 2024-10-31 | — | — | US | disclosed |
| US-12091390-B2 | Rosuvastatin calcium and process for producing intermediate thereof | API CORPORATION (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-2848609-B1 | Crystalline methyl ester of rosuvastatin | LEK PHARMACEUTICALS (SI) | 2018-01-17 | — | — | EP | disclosed |
| US-9102656-B2 | Use of rosuvastatin lactols as medicaments | REDX PHARMA LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9006282-B2 | Rosuvastatin and atorvastatin derivatives | REDX PHARMA LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| CN-104473899-A | Rosuvastatin calcium tablet and preparation method thereof | HENAN RUNHONG PHARMACEUTICAL CO LTD | 2015-04-01 | — | — | CN | disclosed |
| EP-2848609-A1 | Crystalline methyl ester of rosuvastatin | LEK Pharmaceuticals d.d. (SI) | 2015-03-18 | — | — | EP | disclosed |
| WO-2015024925-A1 | MODULATORS OF THE UNCONVENTIONAL SECRETORY PATHWAY FOR USE IN THE TREATMENT OF ALEXANDER DISEASE | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2015-02-26 | — | — | WO | disclosed |
| EP-1863773-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2007-12-12 | — | — | EP | disclosed |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | AEGERION PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007047725-A2 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | AEGERION PHARMACEUTICALS (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007017117-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
| EP-1740164-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | Alcon Inc. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006100689-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005105069-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-6841554-B2 | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | ASTRAZENECA AB (SE) | 2005-01-11 | — | — | US | disclosed |
| US-20030045718-A1 | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | SHIONOGI & CO. LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045718-A1 | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | EIF5B, SF3B5, NT5C3B | HMGCR 149/4885ALDH1A1 1306/4885CYP3A4 401/4885 |
| US-20240360086-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 2111/4885CYP3A4 163/4885 |
| US-12091390-B2 | Rosuvastatin calcium and process for producing intermediate thereof | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 2111/4885CYP3A4 163/4885 |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | HMGCR, MTTP, CETP | HMGCR 1/4885ALDH1A1 2532/4885CYP3A4 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.